Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

885 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The antioxidative stress regulator Nrf2 potentiates radioresistance of oral squamous cell carcinoma accompanied with metabolic modulation.
Matsuoka Y, Yoshida R, Kawahara K, Sakata J, Arita H, Nkashima H, Takahashi N, Hirayama M, Nagata M, Hirosue A, Kuwahara Y, Fukumoto M, Toya R, Murakami R, Nakayama H. Matsuoka Y, et al. Among authors: hirayama m. Lab Invest. 2022 Aug;102(8):896-907. doi: 10.1038/s41374-022-00776-w. Epub 2022 Apr 12. Lab Invest. 2022. PMID: 35414650 Free PMC article.
HMGA2 Contributes to Distant Metastasis and Poor Prognosis by Promoting Angiogenesis in Oral Squamous Cell Carcinoma.
Sakata J, Hirosue A, Yoshida R, Kawahara K, Matsuoka Y, Yamamoto T, Nakamoto M, Hirayama M, Takahashi N, Nakamura T, Arita H, Nakashima H, Nagata M, Hiraki A, Shinohara M, Nakayama H. Sakata J, et al. Among authors: hirayama m. Int J Mol Sci. 2019 May 19;20(10):2473. doi: 10.3390/ijms20102473. Int J Mol Sci. 2019. PMID: 31109142 Free PMC article.
Efficacy of adjuvant chemotherapy with S-1 in stage II oral squamous cell carcinoma patients: A comparative study using the propensity score matching method.
Yoshida R, Nagata M, Hirosue A, Kawahara K, Nakamoto M, Hirayama M, Takahashi N, Matsuoka Y, Sakata J, Nakashima H, Arita H, Hiraki A, Shinohara M, Kikuchi K, Nakayama H. Yoshida R, et al. Among authors: hirayama m. PLoS One. 2020 Apr 15;15(4):e0231656. doi: 10.1371/journal.pone.0231656. eCollection 2020. PLoS One. 2020. PMID: 32294127 Free PMC article.
Extracellular vesicles derived from radioresistant oral squamous cell carcinoma cells contribute to the acquisition of radioresistance via the miR-503-3p-BAK axis.
Yamana K, Inoue J, Yoshida R, Sakata J, Nakashima H, Arita H, Kawaguchi S, Gohara S, Nagao Y, Takeshita H, Maeshiro M, Liu R, Matsuoka Y, Hirayama M, Kawahara K, Nagata M, Hirosue A, Toya R, Murakami R, Kuwahara Y, Fukumoto M, Nakayama H. Yamana K, et al. Among authors: hirayama m. J Extracell Vesicles. 2021 Dec;10(14):e12169. doi: 10.1002/jev2.12169. J Extracell Vesicles. 2021. PMID: 34894384 Free PMC article.
miR-30a attenuates drug sensitivity to 5-FU by modulating cell proliferation possibly by downregulating cyclin E2 in oral squamous cell carcinoma.
Kawahara K, Nagata M, Yoshida R, Hirosue A, Tanaka T, Matsuoka Y, Arita H, Nakashima H, Sakata J, Yamana K, Kawaguchi S, Gohara S, Nagao Y, Hirayama M, Takahashi N, Hirayama M, Nakayama H. Kawahara K, et al. Among authors: hirayama m. Biochem Biophys Rep. 2021 Sep 21;28:101114. doi: 10.1016/j.bbrep.2021.101114. eCollection 2021 Dec. Biochem Biophys Rep. 2021. PMID: 34589618 Free PMC article.
Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration.
Kawaguchi S, Kawahara K, Fujiwara Y, Ohnishi K, Pan C, Yano H, Hirosue A, Nagata M, Hirayama M, Sakata J, Nakashima H, Arita H, Yamana K, Gohara S, Nagao Y, Maeshiro M, Iwamoto A, Hirayama M, Yoshida R, Komohara Y, Nakayama H. Kawaguchi S, et al. Among authors: hirayama m. Cancer Immunol Immunother. 2022 Sep;71(9):2127-2139. doi: 10.1007/s00262-022-03149-w. Epub 2022 Jan 19. Cancer Immunol Immunother. 2022. PMID: 35044489 Free PMC article.
Predictive value of the combination of SMAD4 expression and lymphocyte infiltration in malignant transformation of oral leukoplakia.
Sakata J, Yoshida R, Matsuoka Y, Nagata M, Hirosue A, Kawahara K, Nakamura T, Nakamoto M, Hirayama M, Takahashi N, Nakashima H, Arita H, Ogi H, Hiraki A, Shinohara M, Nakayama H. Sakata J, et al. Among authors: hirayama m. Cancer Med. 2017 Apr;6(4):730-738. doi: 10.1002/cam4.1005. Epub 2017 Mar 3. Cancer Med. 2017. PMID: 28256094 Free PMC article.
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.
Yoshitake Y, Fukuma D, Yuno A, Hirayama M, Nakayama H, Tanaka T, Nagata M, Takamune Y, Kawahara K, Nakagawa Y, Yoshida R, Hirosue A, Ogi H, Hiraki A, Jono H, Hamada A, Yoshida K, Nishimura Y, Nakamura Y, Shinohara M. Yoshitake Y, et al. Among authors: hirayama m. Clin Cancer Res. 2015 Jan 15;21(2):312-21. doi: 10.1158/1078-0432.CCR-14-0202. Epub 2014 Nov 12. Clin Cancer Res. 2015. PMID: 25391695 Clinical Trial.
Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Irie A, Kawahara K, Yatsuda J, Hamada A, Jono H, Yoshida K, Tsunoda T, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y. Tomita Y, et al. Among authors: hirayama m. Clin Cancer Res. 2013 Aug 15;19(16):4508-20. doi: 10.1158/1078-0432.CCR-13-0197. Epub 2013 May 28. Clin Cancer Res. 2013. PMID: 23714729
885 results